Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Black Diamond TherapeuticsRubius TherapeuticsTaysha Gene TherapiesPassage BioAligos Therapeutics
SymbolNASDAQ:BDTXNASDAQ:RUBYNASDAQ:TSHANASDAQ:PASGNASDAQ:ALGS
Price Information
Current Price$25.86$24.30$23.86$15.88$21.61
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.61.61.81.81.5
Analysis Score3.51.13.53.43.5
Community Score2.82.33.93.33.3
Dividend Score0.00.00.00.00.0
Ownership Score1.74.20.81.70.0
Earnings & Valuation Score0.00.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$51.50$23.33$43.92$27.32$35.75
% Upside from Price Target99.15% upside-3.98% downside84.06% upside72.01% upside65.43% upside
Trade Information
Market Cap$934.53 million$1.97 billion$900.98 million$854.84 million$824.27 million
BetaN/A2.37N/AN/AN/A
Average Volume450,2501,706,13191,715451,00470,003
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($1.44) per share$3.44 per shareN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net Income$-35,260,000.00$-163,460,000.00N/AN/AN/A
EPS($16.99)($2.08)N/AN/AN/A
Trailing P/E RatioN/AN/A0.000.000.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-22.28%-77.33%N/AN/AN/A
Return on Assets (ROA)-17.91%-49.05%N/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.43%N/AN/AN/A
Current Ratio29.67%7.15%24.02%18.30%N/A
Quick Ratio29.66%7.15%24.02%18.30%N/A
Ownership Information
Institutional Ownership Percentage65.78%93.74%42.19%67.59%N/A
Insider Ownership PercentageN/A58.40%N/AN/AN/A
Miscellaneous
Employees58204387474
Shares Outstanding36.14 million81.23 million37.76 million53.83 million38.14 million
Next Earnings Date5/11/2021 (Estimated)5/10/2021 (Estimated)6/2/2021 (Estimated)5/10/2021 (Estimated)6/22/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in ...Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in ...
apnews.com - April 14 at 1:09 PM
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept StudyAligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
finance.yahoo.com - April 14 at 8:09 AM
Aligos Therapeutics (NASDAQ:ALGS) Trading Up 6.4%Aligos Therapeutics (NASDAQ:ALGS) Trading Up 6.4%
americanbankingnews.com - April 9 at 3:18 PM
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.6%Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.6%
americanbankingnews.com - April 8 at 12:28 PM
Aligos Therapeutics, Inc.s Lock-Up Period To End  on April 14th (NASDAQ:ALGS)Aligos Therapeutics, Inc.'s Lock-Up Period To End on April 14th (NASDAQ:ALGS)
americanbankingnews.com - April 7 at 1:18 AM
Heres Why Were Not Too Worried About Aligos Therapeutics (NASDAQ:ALGS) Cash Burn SituationHere's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
nasdaq.com - April 6 at 6:47 PM
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $20.87Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $20.87
americanbankingnews.com - April 1 at 11:01 AM
Aligos Therapeutics (NASDAQ:ALGS) Given "Buy" Rating at Jefferies Financial GroupAligos Therapeutics (NASDAQ:ALGS) Given "Buy" Rating at Jefferies Financial Group
americanbankingnews.com - April 1 at 8:16 AM
Aligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeAligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading Volume
americanbankingnews.com - March 31 at 11:40 AM
Aligos Therapeutics (NASDAQ:ALGS) Trading Up 5%Aligos Therapeutics (NASDAQ:ALGS) Trading Up 5%
americanbankingnews.com - March 26 at 11:44 AM
Aligos Therapeutics, Inc. Forecasted to Post Q1 2021 Earnings of ($0.86) Per Share (NASDAQ:ALGS)Aligos Therapeutics, Inc. Forecasted to Post Q1 2021 Earnings of ($0.86) Per Share (NASDAQ:ALGS)
americanbankingnews.com - March 26 at 7:10 AM
Q1 2021 Earnings Forecast for Aligos Therapeutics, Inc. Issued By Piper Sandler (NASDAQ:ALGS)Q1 2021 Earnings Forecast for Aligos Therapeutics, Inc. Issued By Piper Sandler (NASDAQ:ALGS)
americanbankingnews.com - March 26 at 7:10 AM
Aligos Therapeutics (NASDAQ:ALGS) PT Raised to $40.00 at Piper SandlerAligos Therapeutics (NASDAQ:ALGS) PT Raised to $40.00 at Piper Sandler
americanbankingnews.com - March 24 at 11:00 AM
Aligos Therapeutics (NASDAQ:ALGS) Releases  Earnings Results, Misses Estimates By $0.27 EPSAligos Therapeutics (NASDAQ:ALGS) Releases Earnings Results, Misses Estimates By $0.27 EPS
americanbankingnews.com - March 24 at 7:48 AM
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ...Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ...
apnews.com - March 23 at 6:33 PM
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsAligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 23 at 6:33 PM
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First ...Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First ...
apnews.com - March 11 at 7:35 AM
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept StudyAligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
finance.yahoo.com - March 10 at 9:00 AM
Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic InfectionsAligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections
finance.yahoo.com - March 8 at 9:29 AM
Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the LiverAligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver
finance.yahoo.com - February 3 at 8:14 AM
Do Insiders Own Lots Of Shares In Aligos Therapeutics, Inc. (NASDAQ:ALGS)?Do Insiders Own Lots Of Shares In Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
finance.yahoo.com - January 16 at 9:21 AM
Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceAligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 9:39 AM
Aligos (ALGS) in Focus: Stock Moves 5.6% HigherAligos (ALGS) in Focus: Stock Moves 5.6% Higher
nasdaq.com - December 17 at 12:22 PM
Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020
finance.yahoo.com - December 17 at 12:22 PM
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASHAligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
finance.yahoo.com - December 7 at 9:28 AM
DateCompanyBrokerageAction
3/26/2021Black Diamond TherapeuticsHC WainwrightReiterated Rating
1/19/2021Black Diamond TherapeuticsCanaccord GenuityReiterated Rating
1/6/2021Black Diamond TherapeuticsWedbushInitiated Coverage
11/24/2020Black Diamond TherapeuticsBerenberg BankInitiated Coverage
2/24/2020Black Diamond TherapeuticsCowenInitiated Coverage
2/24/2020Black Diamond TherapeuticsJefferies Financial GroupInitiated Coverage
2/24/2020Black Diamond TherapeuticsJPMorgan Chase & Co.Initiated Coverage
3/22/2021Rubius TherapeuticsSVB LeerinkBoost Price Target
1/19/2021Rubius TherapeuticsMorgan StanleyBoost Price Target
3/13/2020Rubius TherapeuticsGuggenheimLower Price Target
9/9/2019Rubius TherapeuticsRobert W. BairdInitiated Coverage
4/12/2021Taysha Gene TherapiesChardan CapitalBoost Price Target
3/1/2021Taysha Gene TherapiesWilliam BlairInitiated Coverage
1/4/2021Taysha Gene TherapiesOppenheimerInitiated Coverage
10/19/2020Taysha Gene TherapiesThe Goldman Sachs GroupInitiated Coverage
12/11/2020Passage BioSmith Barney CitigroupInitiated Coverage
12/11/2020Passage BioCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/24/2021Aligos TherapeuticsPiper SandlerBoost Price Target
11/10/2020Aligos TherapeuticsCantor FitzgeraldInitiated Coverage
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.